-- The global biopharmaceuticals contract manufacturing market exhibited a valuation of USD 13.85 billion in 2022, and it is projected to maintain a robust revenue compound annual growth rate (CAGR) of 9% throughout the forecast period. This substantial growth can be attributed to the increasing demand for biologics, including monoclonal antibodies, vaccines, and therapeutic proteins. These biologics offer enhanced specificity and efficacy in the treatment of chronic diseases, such as cancer and autoimmune disorders, which serves as a significant driving force behind the market's revenue growth.
The prevalence of chronic diseases has been on the rise, creating a greater need for biopharmaceuticals and contributing to the expansion of the market. Additionally, pharmaceutical and biotechnology companies are increasingly outsourcing the manufacturing of biopharmaceuticals. By doing so, these businesses can save time, reduce production costs, and focus on their core competencies while leveraging the expertise of contract manufacturing organizations (CMOs) specialized in biopharmaceuticals.
The escalating complexity of biologics manufacturing and the stringent regulatory requirements surrounding the production and commercialization of these products have further fueled the demand for specialized CMOs. These CMOs possess extensive experience in biologics manufacturing and provide a range of services, including process development, scale-up, and technology transfer. Their expertise enables them to navigate the intricacies of biopharmaceutical production and ensure compliance with regulatory standards, driving the growth of the contract manufacturing market for biopharmaceuticals.
Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/sample-enquiry-form/5968
Market Segments: -
The biopharmaceuticals contract manufacturing market can be segmented based on various factors. These segments include Source Outlook, Service Outlook, Product Outlook, Therapeutic Area Outlook, and Regional Outlook.
In terms of Source Outlook, the market can be divided into two categories: Mammalian and Non-mammalian. Mammalian sources are commonly used for the production of biopharmaceuticals, while Non-mammalian sources encompass alternative systems such as microbial or yeast-based expression platforms.
The Service Outlook segment covers different services provided by contract manufacturing organizations (CMOs). These services include Process Development, Downstream processing, Upstream processing, Fill & Finish Operations, Analytical & QC studies, and Packaging. CMOs offer these services to support the development and production of biopharmaceuticals for their clients.
The Product Outlook segment focuses on the types of biopharmaceutical products that are manufactured through contract manufacturing. It includes various categories such as Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others, and Biosimilars.
The Therapeutic Area Outlook segment encompasses the therapeutic areas for which biopharmaceuticals are developed and manufactured. This includes Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases, and Others.
Finally, the Regional Outlook segment highlights the geographical scope of the market, which includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. These regions represent major markets for biopharmaceutical contract manufacturing, with varying levels of demand and growth opportunities.
Strategic developments in the Biopharmaceuticals Contract Manufacturing Market:
· Lonza Group AG revealed a strategic collaboration with Virios Therapeutics in December 2021 to expedite the advancement of Virios' experimental gene therapy product targeting Huntington's disease.
· Samsung Biologics Co. Ltd. declared in November 2021 that it would expand its manufacturing facility in Incheon, South Korea, in response to the increasing demand for contract manufacturing services for biopharmaceuticals.
· Boehringer Ingelheim GmbH made an announcement in September 2021 about acquiring Abexxa Biologics, a biopharmaceutical company headquartered in the United States that specializes in developing groundbreaking antibody-based therapeutics.
Access Full Report Description with Research Methodology and Table of Content @ https://www.reportsanddata.com/report-detail/biopharmaceuticals-contract-manufacturing-market
Competitive Landscape:
The global Biopharmaceuticals Contract Manufacturing market is home to several major companies that play a significant role in the industry. These companies are Lonza Group AG, Boehringer Ingelheim GmbH, Samsung Biologics Co. Ltd., Thermo Fisher Scientific Inc., Fujifilm Diosynth Biotechnologies, Catalent, Inc., Wuxi Biologics, AbbVie Inc., Cytiva, AGC Biologics renowned for their expertise and capabilities in providing contract manufacturing services for biopharmaceutical products.
One prominent player in the market is Lonza Group AG, known for its extensive experience in bioprocessing and contract manufacturing of biopharmaceuticals. Lonza offers a wide range of services, including cell line development, process development, and cGMP manufacturing, catering to the diverse needs of biopharmaceutical companies.
Another key player is Boehringer Ingelheim GmbH, a leading contract manufacturer that offers comprehensive solutions for biopharmaceutical production. Boehringer Ingelheim has state-of-the-art facilities and expertise in process development, manufacturing, and analytical services, ensuring high-quality and efficient production of biopharmaceuticals.
Read More About:- “Rare Biomarkers Specimen Collection Stabilization Market to Skyrocket, Projected to Reach USD 1983.36 Million by 2032 with a CAGR of 14%: Increasing Demand for Personalized Medicine and Biomarker-Based Diagnosis Drives Growth”.
About Us: Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Info:
Name: John W
Email: Send Email
Organization: Report and Data
Address: 40 Wall St. 28th floor New York City, NY 10005 United States
Phone: +12127101370
Website: https://www.reportsanddata.com/
Release ID: 89096656
Google
RSS